BeOne Medicines

The page describes BeOne Medicines' FDA-approved therapies and their use across cancer indications.

Discover BeOne Medicines’ resources supporting mental health and emotional well-being for people living with cancer, their families, and care partners.

BeOne Medicines’ Expanded Access Program provides investigational medicines to eligible patients who are unable to participate in clinical trials.

Find and explore BeOne Medicines clinical trials across oncology, with study details and contact information for patients and healthcare professionals.

The page describes how the Hopewell campus expansion strengthens U.S. manufacturing, supports oncology innovation, and helps BeOne Medicines deliver cancer medicines worldwide.

BeOne's second-quarter 2026 financial results reflect momentum across its business and progress in reaching patients worldwide, as well as its current business strength and future opportunities.

The page traces the evolution of CLL treatment from chemotherapy to targeted and personalized therapies and describes BeOne Medicines' ongoing research into future treatment options.

Hear Dr. Lydia Scarfo discuss patient-centered care in chronic lymphocytic leukemia (CLL), treatment decision-making, and insights into patient priorities in CLL care.

The BeOne Medicines newsroom provides press releases, media resources, and updates on oncology research, pipeline advancements, and corporate news.

Access BeOne Medicines corporate media resources, including official logos and leadership headshots for approved communications use.

The page reports that John V. Oyler, Co-Founder and CEO of BeOne Medicines, was named the 2025 Entrepreneur Of The Year National Health Award winner by Ernst and Young.

Access the BeOne Medicines media library to download official logos, executive headshots, videos, and other corporate assets for press and media use.

The page describes interns' hands-on experience, mentorship, and professional development during BeOne Medicines' 2026 summer internship program.

BeOne Medicines offers careers on a global oncology team that advances cancer treatments.

BeOne Medicines is a global oncology company that develops therapies for patients worldwide.

The page describes BeOne Medicines' culture, where teams collaborate to advance cancer care for patients worldwide.

The page says BeOne Medicines' leaders combine science with its pipeline to develop treatments for patients globally.

The page describes how BeOne Medicines works to expand access to cancer therapies through research, manufacturing, local access pathways, community collaboration, and philanthropy.

The page describes BeOne Medicines' inclusive culture, growth opportunities, flexible work models, and commitment to patients and innovation.

The page describes how BeOne Medicines' network of more than 40 offices across six continents supports collaboration, operations, and global access to medicines.

The page describes BeOne Medicines' sustainability practices to protect the environment and support long-term societal impact.

The page provides contact options for inquiries about investors, medical information, or general questions, as well as access to support resources and global teams.

BeOne Medicines is a global oncology company that advances cancer care through treatments and therapies and improves outcomes for patients worldwide.

The page describes how BeOne Medicines collects, uses, protects, and manages personal information under its global privacy and data protection policies.

The page outlines the legal conditions, user responsibilities, and rights governing access to and use of the BeOne Medicines website.

BeOne Medicines announces U.S. FDA approval of TEVIMBRA (tislelizumab) with ZIIHERA (zanidatamab-hrii) plus chemotherapy for first-line HER2-positive gastroesophageal cancer. The regimen combines the two named medicines with chemotherapy and carries FDA approval for use as initial treatment in this cancer type.

Aug 2026 · Managed Healthcare ExecutiveNews article

BeOne Medicines reports record second-quarter 2026 revenue of $1.7 billion, up 30 percent year over year, driven by BRUKINSA growth. It also raises its full-year guidance following a quarter that sets a new revenue record, though no revised target is given.

Aug 2026 · flcubeNews article

BeOne Medicines receives U.S. FDA accelerated approval for BEQALZI (sonrotoclax), a BCL2 inhibitor for adults with relapsed or refractory mantle cell lymphoma. The approval is for patients who have received at least two prior systemic therapies, including a BTK inhibitor; the article describes BEQALZI as the first and only BCL2 inhibitor for this setting.

May 2026 · StockTitanNews article

BeOne Medicines entered into a royalty purchase agreement with Royalty Pharma covering IMDELLTRA worldwide sales rights excluding China. The agreement includes an upfront payment of $885 million and could total up to $950 million.

Aug 2025 · StockTitanNews article